Lacticaseibacillus rhamnosus R0011 and Reduced Gastrointestinal Adverse Events

• Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study.

  • 2023-09-14
  • RCT · n = 160
  • Frontiers in gastroenterology (Lausanne, Switzerland) 2
  • • Anya Kiattiweerasak
    • Natsuda Aumpan
    • Soonthorn Chonprasertsuk
    • Bubpha Pornthisarn
    • Sith Siramolpiwat
    • Patommatat Bhanthumkomol
    • Pongjarat Nunanan
    • Navapan Issariyakulkarn
    • Varocha Mahachai
    • Yoshio Yamaoka
    • Ratha-Korn Vilaichone

  • PubMed: 41821821
  • DOI: 10.3389/fgstr.2023.1245993

  5 Insights on

  • Reduced Gastrointestinal Adverse Events

  • High evidence

  probiotic supplementation significantly reduced treatment side effects, including bloating (OR 0.27 [95% CI 0.10 to 0.75], p=0.012), diarrhea (OR 0.23 [95% CI 0.28 to 0.65], p=0.006), nausea (OR 0.05 [95% CI 0.01 to 0.36], p=0.003), and bitter taste (OR 0.14 [95% CI 0.03 to 0.69], p=0.015).

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes